The promise of mRNA technology seemed boundless after the success of the coronavirus vaccines, but Robert F. Kennedy Jr. has ...

Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump administration vs. mRNA vaccines ...

HHS Secretary Robert F. Kennedy Jr. says Moderna (MRNA) has agreed to do another clinical trial to back its newly approved next-gen COVID-19 vaccine. Read more here.

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18-59 years of age who are at increased risk for severe illness from ...

Moderna, Inc. (NASDAQ:MRNA) plans on resubmitting the application later in the year, after it receives efficacy data from an ongoing trial of its influenza shot, mRNA-1010. A scientist surrounded ...

Shares of Moderna MRNA declined nearly 8% yesterday after it announced that it had voluntarily withdrawn a regulatory filing seeking the FDA’s approval for mRNA-1083, its investigational mRNA ...

The Trump administration is waging war against mRNA vaccines despite President Donald Trump having called them the “gold standard” when his admin rolled out the COVID shots […] ...

Moderna (NASDAQ:MRNA) announced on Saturday that the U.S. Food and Drug Administration (FDA) approved its next-gen COVID-19 vaccine, mNEXSPIKE (mRNA-1283), making it the Cambridge, Massachusetts ...

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

This updated mRNA shot still works by teaching the body to make a specific protein that helps your immune system ward off certain diseases. But instead of targeting the entire spike protein on the ...